Time-dependent multivariate analysis on the relative risk of major thrombosis, arterial thrombosis, venous thrombosis, myocardial infarction, stroke plus TIA, and peripheral arterial thrombosis among men and women with polycythemia vera (n = 1638)
| . | 10.1 to 15.0 × 109/L white blood cells*† . | More than 15.0 × 109/L white blood cells*‡ . | |||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Patients with major thrombosis (n = 169) | |||||
| Unadjusted§ | 1.00 (0.67-1.48) | .986 | 1.56 (1.05-2.30) | .028 | |
| Adjusted | |||||
| For age and sex‖ | 0.98 (0.66-1.46) | .922 | 1.48 (1.00-2.19) | .052 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.97 (0.65-1.44) | .859 | 1.39 (0.94-2.07) | .103 | |
| For RF and comorbidity# | 1.09 (0.72-1.67) | .677 | 1.70 (1.10-2.63) | .016 | |
| For cytoreductive and antithrombotic treatment** | 1.06 (0.69-1.62) | .803 | 1.71 (1.10-2.65) | .017 | |
| Patients with arterial thrombosis (n = 121) | |||||
| Unadjusted§ | 1.02 (0.64-1.61) | .945 | 1.41 (0.88-2.28) | .155 | |
| Adjusted | |||||
| For age and sex‖ | 1.00 (0.63-1.59) | .998 | 1.34 (0.83-2.16) | .227 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.98 (0.62-1.55) | .928 | 1.27 (0.78-2.05) | .334 | |
| For RF and comorbidity# | 1.15 (0.71-1.89) | .568 | 1.61 (0.96-2.73) | .074 | |
| For cytoreductive and antithrombotic treatment** | 1.11 (0.68-1.82) | .675 | 1.67 (0.98-2.84) | .058 | |
| Patients with venous thrombosis (n = 51) | |||||
| Unadjusted§ | 0.86 (0.39-1.88) | .703 | 1.94 (0.99-3.80) | .052 | |
| Adjusted | |||||
| For age and sex‖ | 0.85 (0.39-1.86) | .683 | 1.86 (0.95-3.64) | .070 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.85 (0.39-1.85) | .675 | 1.75 (0.89-3.45) | .105 | |
| For RF and comorbidity# | 0.90 (0.40-2.05) | .809 | 1.93 (0.91-4.07) | .086 | |
| For cytoreductive and antithrombotic treatment** | 0.87 (0.38-1.98) | .733 | 1.81 (0.84-3.89) | .127 | |
| Patients with myocardial infarction (n = 41) | |||||
| Unadjusted§ | 1.15 (0.51-2.59) | .730 | 2.46 (1.19-5.09) | .015 | |
| Adjusted | |||||
| For age and sex‖ | 1.13 (0.50-2.55) | .763 | 2.28 (1.11-4.72) | .026 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 1.10 (0.49-2.48) | .811 | 2.13 (1.02-4.44) | .045 | |
| For RF and comorbidity# | 1.32 (0.56-3.10) | .522 | 2.65 (1.19-5.93) | .018 | |
| For cytoreductive and antithrombotic treatment** | 1.32 (0.56-3.10) | .531 | 2.84 (1.25-6.46) | .013 | |
| Patients with stroke/TIA (n = 54) | |||||
| Unadjusted§ | 1.08 (0.56-2.07) | .829 | 0.80 (0.34-1.91) | .617 | |
| Adjusted | |||||
| For age and sex‖ | 1.07 (0.55-2.06) | .850 | 0.77 (0.32-1.83) | .554 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 1.04 (0.54-2.01) | .909 | 0.77 (0.32-1.83) | .547 | |
| For RF and comorbidity# | 1.31 (0.65-2.64) | .454 | 0.93 (0.37-2.32) | .870 | |
| For cytoreductive and antithrombotic treatment** | 1.25 (0.62-2.53) | .541 | 0.93 (0.37-2.34) | .870 | |
| Patients with peripheral arterial thrombosis (n = 21) | |||||
| Unadjusted§ | 0.95 (0.31-2.93) | .933 | 1.43 (0.47-4.38) | .535 | |
| Adjusted | |||||
| For age and sex‖ | 0.94 (0.31-2.89) | .915 | 1.36 (0.44-4.17) | .595 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.95 (0.31-2.93) | .932 | 1.17 (0.38-3.64) | .781 | |
| For RF and comorbidity# | 0.94 (0.28-3.19) | .924 | 1.74 (0.47-6.36) | .406 | |
| For cytoreductive and antithrombotic treatment** | 0.86 (0.25-2.92) | .803 | 1.72 (0.46-6.46) | .425 | |
| . | 10.1 to 15.0 × 109/L white blood cells*† . | More than 15.0 × 109/L white blood cells*‡ . | |||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Patients with major thrombosis (n = 169) | |||||
| Unadjusted§ | 1.00 (0.67-1.48) | .986 | 1.56 (1.05-2.30) | .028 | |
| Adjusted | |||||
| For age and sex‖ | 0.98 (0.66-1.46) | .922 | 1.48 (1.00-2.19) | .052 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.97 (0.65-1.44) | .859 | 1.39 (0.94-2.07) | .103 | |
| For RF and comorbidity# | 1.09 (0.72-1.67) | .677 | 1.70 (1.10-2.63) | .016 | |
| For cytoreductive and antithrombotic treatment** | 1.06 (0.69-1.62) | .803 | 1.71 (1.10-2.65) | .017 | |
| Patients with arterial thrombosis (n = 121) | |||||
| Unadjusted§ | 1.02 (0.64-1.61) | .945 | 1.41 (0.88-2.28) | .155 | |
| Adjusted | |||||
| For age and sex‖ | 1.00 (0.63-1.59) | .998 | 1.34 (0.83-2.16) | .227 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.98 (0.62-1.55) | .928 | 1.27 (0.78-2.05) | .334 | |
| For RF and comorbidity# | 1.15 (0.71-1.89) | .568 | 1.61 (0.96-2.73) | .074 | |
| For cytoreductive and antithrombotic treatment** | 1.11 (0.68-1.82) | .675 | 1.67 (0.98-2.84) | .058 | |
| Patients with venous thrombosis (n = 51) | |||||
| Unadjusted§ | 0.86 (0.39-1.88) | .703 | 1.94 (0.99-3.80) | .052 | |
| Adjusted | |||||
| For age and sex‖ | 0.85 (0.39-1.86) | .683 | 1.86 (0.95-3.64) | .070 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.85 (0.39-1.85) | .675 | 1.75 (0.89-3.45) | .105 | |
| For RF and comorbidity# | 0.90 (0.40-2.05) | .809 | 1.93 (0.91-4.07) | .086 | |
| For cytoreductive and antithrombotic treatment** | 0.87 (0.38-1.98) | .733 | 1.81 (0.84-3.89) | .127 | |
| Patients with myocardial infarction (n = 41) | |||||
| Unadjusted§ | 1.15 (0.51-2.59) | .730 | 2.46 (1.19-5.09) | .015 | |
| Adjusted | |||||
| For age and sex‖ | 1.13 (0.50-2.55) | .763 | 2.28 (1.11-4.72) | .026 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 1.10 (0.49-2.48) | .811 | 2.13 (1.02-4.44) | .045 | |
| For RF and comorbidity# | 1.32 (0.56-3.10) | .522 | 2.65 (1.19-5.93) | .018 | |
| For cytoreductive and antithrombotic treatment** | 1.32 (0.56-3.10) | .531 | 2.84 (1.25-6.46) | .013 | |
| Patients with stroke/TIA (n = 54) | |||||
| Unadjusted§ | 1.08 (0.56-2.07) | .829 | 0.80 (0.34-1.91) | .617 | |
| Adjusted | |||||
| For age and sex‖ | 1.07 (0.55-2.06) | .850 | 0.77 (0.32-1.83) | .554 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 1.04 (0.54-2.01) | .909 | 0.77 (0.32-1.83) | .547 | |
| For RF and comorbidity# | 1.31 (0.65-2.64) | .454 | 0.93 (0.37-2.32) | .870 | |
| For cytoreductive and antithrombotic treatment** | 1.25 (0.62-2.53) | .541 | 0.93 (0.37-2.34) | .870 | |
| Patients with peripheral arterial thrombosis (n = 21) | |||||
| Unadjusted§ | 0.95 (0.31-2.93) | .933 | 1.43 (0.47-4.38) | .535 | |
| Adjusted | |||||
| For age and sex‖ | 0.94 (0.31-2.89) | .915 | 1.36 (0.44-4.17) | .595 | |
| For disease duration, prior thrombosis, and prior hemorrhage¶ | 0.95 (0.31-2.93) | .932 | 1.17 (0.38-3.64) | .781 | |
| For RF and comorbidity# | 0.94 (0.28-3.19) | .924 | 1.74 (0.47-6.36) | .406 | |
| For cytoreductive and antithrombotic treatment** | 0.86 (0.25-2.92) | .803 | 1.72 (0.46-6.46) | .425 | |
Reference category: ≤ 10.0 × 109/L (n = 990 [62.0%]).
n = 365 (22.9%).
n = 241 (15.1%).
Model 1: white blood cells (3 categories).
Model 2: model 1 plus age (2 categories), sex.
Model 3: model 2 plus time from PV diagnosis to recruitment (2 categories), thrombotic or hemorrhagic events prior to recruitment (yes/no).
Model 4: model 3 plus smoking (yes/no), history of diabetes (yes/no), hypertension (yes/no), intermittent claudication (yes/no), erythromelalgia (yes/no), splenomegaly, (yes/no), circulating immature cells (yes/no), hematocrit (tertiles), platelet count (tertiles), and total blood cholesterol (2 categories).
Model 5: model 4 plus phlebotomy use (yes/no), interferon use (yes/no), hydroxyurea use (yes/no), antiplatelet use (yes/no), anticoagulant use (yes/no), 32P use (yes/no), busulfan use (yes/no), chlorambucil use (yes/no), and pipobroman use (yes/no).